Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zenas BioPharma
Zenas BioPharma is developing immune-based therapies for autoimmune and rare diseases.
Biotech
Zenas stock sinks on autoimmune readout despite hitting endpoint
With the result falling short of the bar Amgen set in another study, investors sent Zenas’ share price down 48% to $18 in premarket trading.
Nick Paul Taylor
Jan 5, 2026 9:30am
Zenas autoimmune drug prompts 95% drop in lesions in MS study
Oct 27, 2025 9:25am
Royalty bestows Zenas with $300M for autoimmune approval push
Sep 2, 2025 11:07am
J&J innovator vaults to Valo—Chutes & Ladders
Apr 11, 2025 8:30am
Former FDA deputy joins AI biotech's board—Chutes & Ladders
Mar 21, 2025 8:30am
Biophama VC, deal values and exits all rise in Q3: Pitchbook
Nov 20, 2024 6:15am
